Enhancement of Tumor Perfusion and Antiangiogenic Therapy in Murine Models of Clear Cell Renal Cell Carcinoma Using Ultrasound-Stimulated Microbubbles
Juan Wang,Tingting Luo,Jianghong Chen,Zheng Liu,Juan Wang,Xiaolin Zhang,Hui Li,Yulin Ma,Fan Zhang,Hongjuan Ju,Wengang Wang,Yueheng Wang,Qiong Zhu
DOI: https://doi.org/10.1016/j.ultrasmedbio.2024.01.006
IF: 3.694
2024-02-05
Ultrasound in Medicine & Biology
Abstract:Objective To explore the effect of ultrasound-stimulated microbubble cavitation (USMC) on enhancing antiangiogenic therapy in clear cell renal cell carcinoma. Materials and Methods We explored the effects of USMC with different mechanical indices (MIs) on tumor perfusion, 36 786-O tumor-bearing nude mice were randomly assigned into four groups: (i) control group, (ii) USMC 0.25 group (MI = 0.25), (iii) USMC 1.4 group (MI = 1.4) (iv) US 1.4 group (MI = 1.4). Tumor perfusion was assessed by contrast-enhanced ultrasound (CEUS) before the USMC treatment and 30 min, 4h and 6h after the USMC treatment, respectively. Then we evaluated vascular normalization(VN) induced by low-MI (0.25) USMC treatment, 12 tumor-bearing nude mice were randomly divided into two groups: (i) control group (ii) USMC 0.25 group. USMC treatment was performed, and tumor microvascular imaging and blood perfusion were analyzed by MicroFlow imaging (MFI) and CEUS 30 min after each treatment. In combination therapy, a total of 144 tumor-bearing nude mice were randomly assigned to six groups (n = 24): (i) control group, (ii) USMC 1.4 group, (iii) USMC 0.25 group, (iv) bevacizumab(BEV) group, (v) USMC 1.4 +BEV group, (vi) USMC 0.25 +BEV group. BEV was injected on the 6th, 10th, 14th, and 18th d after the tumors were inoculated, while USMC treatment was performed 24 h before and after every BEV administration. We examined the effects of the combination therapy through a series of experiments. Results Tumor blood perfusion enhanced by USMC with low MI (0.25)could last for more than 6h, inducing tumor VN and promoting drug delivery. Compared with other groups, USMC 0.25 +BEV combination therapy had the strongest inhibition on tumor growth, led to the longest survival time of the mice. Conclusion The optimized USMC is a promising therapeutic approach that can be combined with antiangiogenic therapy to combat tumor progression.
radiology, nuclear medicine & medical imaging,acoustics